Achilles Therapeutics Investor Relations Material
Latest events
Q3 2024
14 Nov, 2024
Q2 2024
14 Aug, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Achilles Therapeutics plc
Access all reports
Achilles Therapeutics plc is a biopharmaceutical company based in the United Kingdom, focused on developing precision T cell therapies targeting cancer. Using its proprietary platform, Achilles designs therapies that target clonal neoantigens—unique markers on tumor cells—enabling a personalized approach to treatment. The company’s therapeutic programs are primarily aimed at treating solid tumors, including lung and melanoma cancers. The company is headquartered in London, United Kingdom, and its shares are listed on the NASDAQ.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
ACHL
Country
🇺🇸 United States